A limited contribution of common genetic variants to variability in wet AMD treatment response was observed, while rare protein-altering variants in the C10orf88 and UNC93B1 genes associated with a worse response to anti-VEGF therapy [15]. The gene discussed is UNC93B1; the disease is wet macular degeneration.